Holen Sie sich die Stockscreener-App
15.78
0.06%
0.010
Vorhandelsmarkt:
15.67
-0.11
-0.70%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.77
Offen:
$15.77
24-Stunden-Volumen:
2.19M
Relative Volume:
0.73
Marktkapitalisierung:
$1.67B
Einnahmen:
$2.18B
Nettoeinkommen (Verlust:
$-64.32M
KGV:
-16.37
EPS:
-0.9641
Netto-Cashflow:
$91.18M
1W Leistung:
-0.69%
1M Leistung:
-10.09%
6M Leistung:
-29.27%
1J Leistung:
-24.64%
1-Tages-Spanne:
$15.39
$16.00
1-Wochen-Bereich:
$14.68
$16.09
52-Wochen-Spanne:
$10.41
$25.32
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
15.78 | 1.66B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2025-12-09 | Eingeleitet | Wedbush | Outperform |
| 2025-11-05 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a Potential 43.7% Upside in the Biotech Sector - DirectorsTalk Interviews
(SRPT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Sarepta Therapeutics (SRPT) Q1 earnings and revenues top estimates - MSN
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
ING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Exclusive | Startup Hunts for a Better Duchenne Gene Therapy - WSJ
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Is Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook? - Yahoo Finance
SRPT: Strong financials and pipeline progress drive confidence in growth and regulatory stability - TradingView
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy - Yahoo Finance
SRPT: Strong financials and pipeline progress drive growth, with pivotal data expected this year - TradingView
SRPT vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
SRPT: Strong financials and pipeline progress drive confidence amid leadership transition - TradingView
Sarepta Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors - TMX Newsfile
Sarepta Therapeutics, Inc. $SRPT Shares Sold by BNP Paribas Financial Markets - MarketBeat
A Look At Sarepta Therapeutics (SRPT) Valuation After New Shelf Registration For Potential Share Offering - Sahm
Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy - Insider Monkey
Sarepta Therapeutics (SRPT) director receives 16,875 RSUs equity grant - Stock Titan
Sarepta Therapeutics (SRPT) director receives 16,875-share RSU equity award - Stock Titan
Sarepta Shareholders Approve 2026 Equity and ESPP Plans - The Globe and Mail
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report? - Yahoo Finance
Sarepta faces earnings test as ELEVIDYS slows, siRNA pipeline builds - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Sarepta faces earnings test as ELEVIDYS slows, siRNA pipeline builds By Investing.com - Investing.com Nigeria
Sarepta (SRPT) awards director Barry Richard 16,875 RSUs - Stock Titan
Sarepta Therapeutics Adopts 2026 Equity Incentive and Employee Stock Purchase Plans – 8-K SEC Filing Summary - Minichart
Earnings call transcript: Sarepta’s Q1 2026 earnings beat expectations - Investing.com
Sarepta Q1 2026 slides: profitability returns amid commercial reset - Investing.com
Sarepta (SRPT) investors approve 2026 stock plans, director slate and KPMG - Stock Titan
SRPT: All proposals passed amid board focus on stability, CEO succession, and performance improvement - TradingView
Acting US FDA chief meets with rare disease groups to mend fences - marketscreener.com
Sarepta Therapeutics, Inc. (AB3A.F) Stock Price, News, Quote & History - Yahoo Finance
SRPT DEADLINE TOMORROW: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class ActionSRPT - TMX Newsfile
Sarepta Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
Responsive Playbooks and the SRPT Inflection - Stock Traders Daily
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion - marketscreener.com
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Number of shareholders of Sarepta Therapeutics, Inc. – MIL:1SRPT - TradingView
Sarepta Therapeutics Outlines 2026 Priorities on Strong Cash PositionPeak Earnings Alert - newsline.com
Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | PTC Therapeutics, Sarepta Therapeutics, Taiho Pharma, Regenxbio, Fibrogen, Roche - Barchart.com
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo Finance
In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities - Insider Monkey
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):